Other languages LENSAR, Inc.

Equities

LNSR

US52634L1089

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-02 EDT			5-day change	1st Jan Change
3.12 ^USD	+1.63%		-9.04%	-11.11%

03-04	Transcript : LENSAR, Inc., Q4 2023 Earnings Call, Mar 04, 2024
03-04	LENSAR, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LENSAR, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-04
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-04
Top Premarket Gainers	11-28
LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
LENSAR, Inc. Announces Retirement of John P. McLaughlin from the Board, Effective October 31, 2023	23-10-13
LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Lensar, Inc. Reports Adoption of Ally System in Multi-Center Ophthalmology Groups	23-07-24
LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
LENSAR, Inc. Provides Revenue Guidance for the Fiscal 2023	23-03-16
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-16
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-16
LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09
Lensar, Inc. Announces Application for Certification of the Ally Adaptive Cataract Treatment System in the Eu	22-09-08
LENSAR, Inc. Announces First Patients Treated with LENSAR's(R) ALLY(TM) Adaptive Cataract Treatment System	22-08-16
LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08
Earnings Flash (LNSR) LENSAR Reports Q2 Revenue $8M	22-08-08
LENSAR Secures FDA Clearance of ALLY Adaptive Cataract Treatment System	22-06-13
LENSAR, Inc. Receives U.S. FDA Clearance of Ally(Tm) Adaptive Cataract Treatment System	22-06-13
LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-09
Earnings Flash (LNSR) LENSAR Posts Q1 Revenue $9.3M, vs. Street Est of $8.71M	22-05-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages LENSAR, Inc.

Equities

LNSR

US52634L1089

Other languages

Filters